Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2011 1
2012 4
2013 3
2014 1
2015 1
2016 2
2017 5
2018 4
2019 2
2021 1
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study.
Mauro FR, Scalzulli PR, Scarfò L, Minoia C, Murru R, Sportoletti P, Frigeri F, Albano F, Di Renzo N, Sanna A, Laurenti L, Massaia M, Cassin R, Coscia M, Patti C, Pennese E, Tafuri A, Chiarenza A, Galieni P, Perbellini O, Selleri C, Califano C, Ferrara F, Cuneo A, Murineddu M, Palumbo G, Scortechini I, Tedeschi A, Trentin L, Varettoni M, Pane F, Liberati AM, Merli F, Morello L, Musuraca G, Tani M, Ibatici A, Regazzoni G, Di Candia M, Palma M, Arienti D, Molica S. Mauro FR, et al. Among authors: sanna a. Cancers (Basel). 2024 Mar 20;16(6):1228. doi: 10.3390/cancers16061228. Cancers (Basel). 2024. PMID: 38539561 Free PMC article.
Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study.
Autore F, Visentin A, Deodato M, Vitale C, Galli E, Fresa A, Fazzi R, Sanna A, Olivieri J, Scortechini I, Del Principe MI, Sportoletti P, Schiattone L, Maschio N, Facchinelli D, Marchesi F, Coscia M, Tedeschi A, Trentin L, Innocenti I, Candoni A, Busca A, Pagano L, Laurenti L. Autore F, et al. Among authors: sanna a. Am J Hematol. 2024 May;99(5):982-984. doi: 10.1002/ajh.27247. Epub 2024 Feb 11. Am J Hematol. 2024. PMID: 38343033 No abstract available.
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: sanna a. Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29. Am J Hematol. 2023. PMID: 37382471 No abstract available.
Corrigendum to < Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience><Translational Oncology, 26C (2022) 101552]>
Capone M, Peruzzi B, Palterer B, Bencini S, Sanna A, Puccini B, Nassi L, Salvadori B, Statello M, Carraresi A, Stefanelli S, Orazzini C, Minuti B, Caporale R, Annunziato F. Capone M, et al. Among authors: sanna a. Transl Oncol. 2023 Apr;30:101631. doi: 10.1016/j.tranon.2023.101631. Epub 2023 Feb 10. Transl Oncol. 2023. PMID: 36801075 Free PMC article. No abstract available.
PIEZO1 mutations impact on early clinical manifestations of myelodysplastic syndromes.
Attardi E, Andolfo I, Russo R, Tiberi L, Raddi MG, Rosato BE, Marra R, Formicola D, Del Giudice F, Brogi A, Consagra A, Amato C, Sanna A, Artuso R, Iolascon A, Santini V. Attardi E, et al. Among authors: sanna a. Am J Hematol. 2023 Apr;98(4):E72-E75. doi: 10.1002/ajh.26863. Epub 2023 Feb 14. Am J Hematol. 2023. PMID: 36695705 Free article. No abstract available.
Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study.
Visentin A, Mauro FR, Catania G, Fresa A, Vitale C, Sanna A, Mattiello V, Cibien F, Sportoletti P, Gentile M, Rigolin GM, Quaglia FM, Murru R, Gozzetti A, Molica S, Marchetti M, Pravato S, Angotzi F, Cellini A, Scarfò L, Reda G, Coscia M, Laurenti L, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: sanna a. Front Oncol. 2022 Nov 21;12:1033413. doi: 10.3389/fonc.2022.1033413. eCollection 2022. Front Oncol. 2022. PMID: 36479077 Free PMC article.
Coexisting conditions and concomitant medications do not affect venetoclax management and survival in chronic lymphocytic leukemia.
Frustaci AM, Del Poeta G, Visentin A, Sportoletti P, Fresa A, Vitale C, Murru R, Chiarenza A, Sanna A, Mauro FR, Reda G, Gentile M, Varettoni M, Baratè C, Borella C, Greco A, Deodato M, Zamprogna G, Laureana R, Cipiciani A, Galitzia A, Curto Pelle A, Morelli F, Malvisi L, Coscia M, Laurenti L, Trentin L, Montillo M, Cairoli R, Tedeschi A. Frustaci AM, et al. Among authors: sanna a. Ther Adv Hematol. 2022 Oct 10;13:20406207221127550. doi: 10.1177/20406207221127550. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36246422 Free PMC article.
Rapid evaluation of T cell clonality in the diagnostic work-up of mature T cell neoplasms: TRBC1-based flow cytometric assay experience.
Capone M, Peruzzi B, Palterer B, Bencini S, Sanna A, Puccini B, Nassi L, Salvadori B, Statello M, Carraresi A, Stefanelli S, Orazzini C, Minuti B, Caporale R, Annunziato F. Capone M, et al. Among authors: sanna a. Transl Oncol. 2022 Dec;26:101552. doi: 10.1016/j.tranon.2022.101552. Epub 2022 Sep 30. Transl Oncol. 2022. PMID: 36183675 Free PMC article.
34 results